Technology
Health
Medical

Oxford Immunotec Global

$17.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (0.51%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell OXFD and other stocks, options, ETFs, and crypto commission-free!

About

Oxford Immunotec Global Plc operates as a medical diagnostics company, which develops and commercializes proprietary tests for under-served immune-regulated conditions. Its current product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Read More Its products include T-SPOT.TB, T-SPOT.CMV, and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.

Employees
457
Headquarters
Abingdon, Oxfordshire
Founded
2013
Market Cap
463.75M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
131.58K
High Today
$17.84
Low Today
$17.50
Open Price
$17.77
Volume
67.11K
52 Week High
$19.19
52 Week Low
$11.66

Collections

Technology
Health
Medical
2013 IPO
UK
Europe

News

Yahoo FinanceMar 14

Moving Average Crossover Alert: Oxford Immunotec Global

Oxford Immunotec Global PLC (OXFD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

18
Seeking AlphaMar 12

Oxford Immunotec Global PLC (OXFD) Presents At Cowen And Company 39th Annual Health Care Conference - Slideshow

The following slide deck was published by Oxford Immunotec Global PLC in conjunction with this event. 1 19 Click to enlarge Notes:...

8
Seeking AlphaMar 12

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q4 2018 Results - Earnings Call Transcript

Oxford Immunotec Global PLC (NASDAQ:OXFD) Q4 2018 Results Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Karen Koski - VP, Strategy and IR Peter Wrighton-Smith - CEO Rick Altieri - CFO Conference Call Participants Catherine Schulte - Baird Chris Lin - Cowen Bill Quirk - Piper Jeffrey Operator Ladies and gentlemen, thank you for standing by. Welcome to the Oxford Immunotec Fourth Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference c...

12

Earnings

-$0.70
-$0.50
-$0.30
-$0.10
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected Apr 30, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.